The trial of alum-formulated GAD (GAD-alum) treatment in recent onset of type 1 diabetes patients showed that it does preservation of residual insulin secretion, although it did not change the insulin requirement.[27–29]. The gene discussed is INS; the disease is type 1 diabetes mellitus.